Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cue Biopharma
Boston, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Cue Biopharma's lead program, CUE-101, targeting HPV+ head and neck cancer, reported a 50% overall response rate in Phase 1 (with pembrolizumab) including new complete responses and promising survival data; preclinical and early-stage clinical assets include those for autoimmune diseases and glioblastoma multiforme[4].
- Therapeutic areas
- OncologyImmunology
- Modalities
- BiologicBispecific molecule
- Industry
- Biotech
02
Partnerships
Boehringer Ingelheim
Beyond the preview
Go deeper on Cue Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cue Biopharma.